secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0001213900-24-010227
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PBAX amends merger agreement with CERo, secures $2M PIPE, and target qualifies for potential $4-6M grant
--------------------------------------------------------------------------------

- Amendment to BCA removes minimum cash condition, resets earnout price targets based on Series A conversion price, and increases shares issuable to CERo stockholders from ~4.65M to 5.0M shares.
- PIPE financing of $2.0M from accredited investor in exchange for Series A Preferred Stock and warrants to purchase 125,000 shares; closing contingent on business combination.
- CERo selected as finalist for $4-6M subsidized grant from Cancer Focus Fund at MD Anderson for CER-1236 trial in AML; grant is not assured.
- PIPE securities issued in reliance on Section 4(a)(2) and Rule 506 of Regulation D; not registered under Securities Act.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024010227/0001213900-24-010227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024010227/ea192779-8k425_phoenix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-010227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer